


12th INTERNATIONAL WORKSHOP ON **HIV PEDIATRICS**

SAN FRANCISCO, CA, USA • 16 - 17 NOVEMBER 2020

A photograph of the Golden Gate Bridge in San Francisco, California, taken during sunset. The bridge's iconic orange-red towers and suspension cables are silhouetted against a soft, orange-hued sky. A large, bright full moon is visible in the upper left portion of the sky. The bridge spans across a body of water, with hills visible in the background.

MEETING PROSPECTUS



INTRODUCTION

The **International Workshop on HIV Pediatrics** is a key platform that brings together researchers, clinicians, NGO representatives, program implementers, government representatives, and other stakeholders working in the field of HIV Pediatrics. The size and the atmosphere of the workshop facilitates discussion and interaction between participants. Eleven successful workshops have been convened since its inception; in Cape Town, Vienna, Rome, Washington, Kuala Lumpur, Australia, Vancouver, Durban, Paris, Amsterdam, and Mexico City.


• UNIQUE MEETING FEATURES

- Research in prevention and treatment of HIV in **pregnant/lactating women, infants, children, and adolescents** are discussed
- A **good representation of all organizations involved** in HIV treatment and care in HIV Pediatrics.
- **Special Session** to address most recent research
- Young investigator awards for **best oral presentation** and **best poster presentation**.
- 6 dedicated **poster walks**
- 28 **(mini-) oral presentation**
- An extraordinary record of supporting **scientific achievement** as demonstrated in the success across the cascade from abstract presentation to **publication**


FACTS AND FIGURES



PROFESSIONAL ROLE



WORKPLACE TYPE





WELCOME MESSAGE

We are proud to announce the **International Workshop on HIV Pediatrics 2020**, scheduled on 16 and 17 November 2020, in San Francisco, CA, USA. Research in pediatric, adolescent, and maternal HIV infection continues to be a neglected area at major scientific HIV conferences, yet it is critically needed to achieve an AIDS-free generation.

The San Francisco Bay Area comprises a large and culturally and socioeconomically diverse group of communities that have experienced the HIV and AIDS epidemic in different ways. The East and West Bay areas of San Francisco constitute a “tale of two cities”, with contrasting epidemiology of youth with HIV. In San Francisco, the HIV epidemic primarily affected young white men who had sex with men, while in Oakland the epidemic has disproportionately affected African-American and Latino men who had sex with men or who injected drugs, and, secondarily, women whose partners were infected and/or who directly injected drugs themselves. As a result, children with perinatally-acquired infection were far more common in the East Bay than in San Francisco; with routine testing and treatment of HIV in pregnancy, perinatal transmission has diminished and many of our youngest patients are now international adoptees or are immigrants from other developing countries. The contrasting epidemiology of HIV in children and youth in San Francisco and implications of these differences for HIV prevention and care in these disparate communities will be discussed at the upcoming International HIV Pediatrics Workshop.

The **International Workshop on HIV Pediatrics** is the only meeting entirely devoted to research in prevention and treatment of HIV infections in infants, children, and adolescents, making it the premier forum for the world’s leading researchers. The workshop has been held annually in conjunction with the International AIDS Conference since 2009, bringing together between 200-300 global experts in pediatric, adolescent, and maternal HIV research each year.

The program includes oral abstract and poster presentations, state-of-the-art lectures from invited speakers, and more informal and interactive fora, including debates and panel discussions. We have a diverse community of participants from around the world, including junior and senior investigators involved in a broad range of disciplines. They gather in an interactive setting that provides a platform for presentation and discussion of the latest developments in the field, encourages young investigators to engage in the field of pediatric and perinatal HIV research, and stimulates new research activities and collaborations.

We invite you to join us at the **International Workshop on HIV Pediatrics 2020** and look forward to welcoming you.

Lynne Mofenson & Elaine Abrams
Workshop Chairs

Theodore Ruel & Ann Petru
Local Chairs 2020

CHAIRS



Lynne Mofenson, MD
Elizabeth Glaser
Pediatric AIDS
Foundation,
USA



Elaine Abrams, MD
Columbia University,
USA



Theodore Ruel, MD
UCSF Benioff
Children’s Hospital,
San Francisco,
USA



Ann Petru, MD
UCSF Benioff
Children’s Hospital
Oakland, USA





NEEDS STATEMENT

Although we have witnessed a dramatic global scale-up of antiretroviral treatment (ART) as well as efforts to prevent mother-to-child HIV transmission (PMTCT) in the last decade, there were 180,000 new pediatric infections in 2018 and an estimated 1.8 million children under 15 years of age are living with HIV. Children are substantially less likely than adults to be diagnosed, initiate treatment, and achieve durable viral suppression. Currently, only 52% have access to treatment (only 26% in Western and Central Africa). Treatment of pediatric HIV infection, particularly of infants and young children, remains complex and problematic, with continued use of suboptimal ART formulations and regimens. Furthermore, adolescents are one of the most rapidly growing populations with HIV. 20% of new HIV infections globally occur among adolescent girls and young women, despite accounting for only 10% of the adult population. In 2017 there were an estimated 340,000 new HIV infections among youth 15-24 years. HIV was the leading cause of death among adolescents living in Africa and the fifth leading cause of death in adolescents globally in 2016. Uptake of HIV testing among adolescents has remained low, programs continue to struggle to reach and retain adolescents in care, and adherence to treatment has special challenges for this age group, particularly among those with perinatal infection aging-up into adolescence and young adulthood.

As research to improve pediatric HIV diagnosis and care is ongoing, new scientific questions of critical importance have also emerged. In settings with mature ART programs, an increasing proportion of new pediatric infections are being attributed to women acquiring HIV infection during pregnancy and breastfeeding. Increasing rates of pre-treatment antiretroviral (ARV) drug resistance, particularly to non-nucleoside reverse transcriptase inhibitor drugs, are being detected among newly diagnosed infants, which may reduce response to ART. Additionally, with more than 1.5 million pregnant women globally receiving ART, there are increasing concerns about the long-term impact of in utero and postnatal exposures to medications for those children who escape HIV. Currently, an estimated 20% of all infants born in sub-Saharan Africa are HIV- and ARV-exposed during pregnancy and the postnatal period.

Furthermore, the pediatric HIV cure and remission agenda is an important emerging area of research. Innovations in early infant diagnosis such as point-of-care tests, have facilitated earlier identification of HIV infection during infancy, providing exciting new opportunities to study acute infection and very early treatment in neonates and promising remission strategies. The cure research agenda in children is unique from that in adults due to timing of infection (during infancy, a time of dramatic immunologic maturation and changes), as well as differing response to immunologic approaches, such as vaccines, in infants than seen in adults.

Target Audience

- Researchers
- Clinicians
- Nurses
- Industry specialists working in academic settings, hospitals, and non-governmental organizations (NGO)

Estimated Number of In-person Participants

80

Estimated Number of Virtual Participants

80

Target Region

Global



The International Workshop on HIV Pediatrics is Unique

Many researchers globally are focusing attention on the previously mentioned issues and other relevant scientific questions that require urgent attention and investigation. However, despite the critical importance of these topics, research in pediatric, adolescent, and maternal HIV infection is often neglected at major scientific HIV conferences. For example, at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI), pediatric HIV was included in only one of eight plenary sessions, one of 14 abstract sessions, and one of nine symposia over the course of the three-day meeting. Therefore, in collaboration with leading experts in the field, we have established a highly focused international workshop on the prevention and treatment of pediatric HIV infection—the **International Workshop on HIV Pediatrics**.

The overall objective of the workshop is to stimulate research that will advance prevention and treatment strategies for infants, children, and adolescents. The aims of the workshop are to provide a platform for presentation and discussion of the latest developments in the field, to gather leading researchers involved in pediatric and perinatal HIV in a stimulating, interactive forum, and to promote the next generation of researchers by supporting early career investigators.

The **International Workshop on HIV Pediatrics** is the only meeting entirely devoted to research in prevention and treatment of HIV infections in infants, children, and adolescents, making it the premier forum for the world's leading researchers. The workshop has been held annually in conjunction with the International AIDS Conference since 2009, bringing together between 200-300 global experts in pediatric, adolescent, and maternal HIV research each year. The program includes oral abstract and poster presentations, state-of-the-art lectures from invited speakers and more informal and interactive fora, including debates and panel discussions. The workshop provides an interactive platform for presentation and discussion of the latest developments in the field, encourages young investigators to engage in the field of pediatric and perinatal HIV research, and stimulates new research activities and collaborations.

The workshop explicitly supports participation of a diverse community of delegates, including women, racial and ethnic minorities, and investigators from low and middle income countries. The workshop brings together junior and senior investigators across a range of disciplines (pediatrics, adolescent medicine, virology, immunology, pharmacology, obstetrics/gynecology, epidemiology, and behavioral sciences) to share knowledge and experience across critical content areas including HIV treatment and management, drug development, prevention of mother to child transmission, co-infections and comorbidities, pediatric cure research, and implementation science.

The workshop provides an interactive platform for analysis, discussion, and debate of new scientific findings as well as an opportunity to consider implications for clinical care and program policy. Finally, by posting all workshop presentations online, study results and state-of-the-art analyses are broadly disseminated beyond the walls of the conference venue to the global community.

Enduring Materials

The invited lectures given at this workshop will be freely accessible and widely disseminated to reach thousands of virtual participants beyond the walls of the workshop venue. This will increase the impact of the workshop even further.

Professionals will be able to watch videos of the presentations given and download slide decks from our professional online platform www.academicmedicaleducation.com. Academic Medical Education is a premier online platform offering scientific materials in special topic areas and proceedings of workshops. Visitors of the website will have full access to:

- Abstract Books
- Workshop Reports
- Workshop Presentations
- Webcasts





Meeting Objectives

The overall objective of this workshop is to stimulate research that will advance the development of prevention and treatment strategies for infants, children, and adolescents. The meeting aims to provide a platform for presentation and discussion of the latest developments in the field, to gather experts involved in pediatric and perinatal HIV, and to promote the next generation of researchers in the field through support of junior investigator participation, particularly those from low-income countries in this unique workshop.

The meeting aims at:

- Providing updates on the latest research into new pediatric antiretroviral drugs, treatment, and cure strategies in children and adolescents
- Understanding of available prevention technologies and their application for prevention of HIV in adolescents in high- and low-resource settings; this information may translate into preventive interventions for high-risk adolescents in different settings
- Sharing results from implementation science research on how to optimally implement proven interventions for prevention of mother-to-child HIV transmission and pediatric care and treatment in developing countries
- Understanding risks of HIV transmission to pregnant and lactating women and implications for the child
- Evaluating optimal antiretroviral therapy in pregnancy and breastfeeding, the effect of such treatment on pregnancy and infant outcome, and potential long-term effects of HIV and antiretroviral exposure on the HIV-exposed but uninfected child as they age
- Understanding complications and comorbidities of long-term HIV infection and its therapy, in order to improve management of HIV in children
- Enhancing communication and collaboration between both junior- and senior-level, international researchers (from academia, government, and industry) and clinicians to promote the exchange of ideas, results, and technologies leading to successful translation into prevention and treatment of HIV
- Disseminating knowledge and data exchanged by workshop participants beyond the audience of the live event through posting of all presentations on the workshop website, thus maximizing the impact of the workshop by reaching the whole HIV research community

Learning Objectives

After attending this workshop the participant will be able to:

- Describe the diversity of the HIV pediatric epidemic worldwide
- Summarize optimal treatment and management strategies of HIV infection in infants, children, and adolescents
- Describe innovations in pediatric treatment, including new drugs, new formulations, and new modalities such as immune-based treatment
- Outline treatment options for HIV-positive women during pregnancy and breastfeeding
- Describe the latest research on potential pediatric HIV cure and remission
- Describe major co-infections in HIV-positive children, such as tuberculosis and hepatitis, and their management
- Describe the special issues related to HIV infection in adolescents and young people, and HIV prevention and programming options for youth
- Reflect on potential effects of HIV *in utero* or postnatal antiretroviral exposure on HIV-exposed but uninfected children
- Describe models of optimal HIV program implementation of prevention and treatment in infants, children, adolescents, and pregnant and lactating women



WORLD'S LEADING EXPERTS

The workshop is led by a diverse group of the foremost researchers in the field, including researchers from the United States, Europe, and Africa. Together, this group of renowned scientists oversee the workshop, including the development of the meeting agenda, abstract review and selection, junior investigator awards, and organization and implementation of the two-day event. The Organizing Committee (OC) identifies speakers based on their knowledge, experience, scientific and geographical background, presentation skills, influence, and reach in the community. Special efforts are made to achieve gender and ethnic diversity among invited speakers and moderators, and to include speakers from both high- and low-income countries. Several members of the OC regularly involve their community advisory and youth boards to elicit ideas for the workshops.

ORGANIZING COMMITTEE



Elaine Abrams
MD

ICAP Mailman School of
Public Health, Columbia
University,
USA



Charles Boucher
MD, PhD

Erasmus Medical
Center,
The Netherlands



Mark Cotton
MD, PHD

Stellenbosch University,
South Africa



Patricia Flynn
MD

St. Jude Children's
Hospital,
USA



Carlo Giaquinto
MD

University of Padova,
Italy



Lynne Mofenson
MD

Elizabeth Glaser
Pediatric AIDS
Foundation,
USA



Ann Petru, MD

UCSF Benioff
Children's Hospital
Oakland, USA



Thanyawee Puthanakit
MD

Chulalongkorn University,
Thailand



Theodore Ruel, MD

UCSF Benioff
Children's Hospital,
San Francisco,
USA



Nadia Sam-Agudu, MD,
CTropMed

Institute of Human Virology
Nigeria



Gareth Tudor-Williams
MD

Imperial College London,
United Kingdom



SCIENTIFIC COMMITTEE

The members of the Scientific Committee (SC) are hand-picked by the OC and the workshop secretariat based on their significant contributions and commitment to the field. They assist the OC by providing them with topic and speaker suggestions. In addition, members of the SC participate in reviewing submitted abstracts and play an active role during the workshop.

- **Moherndran Archary, MBChB, DOH, FCPaedS** - University of KwaZulu Natal, South Africa
- **Jason Brophy, MD** - Children's Hospital of Eastern Ontario, Canada
- **Tsungai Chipato, MBChB** - University of Zimbabwe, Zimbabwe
- **Polly Clayden** - HIV i-Base, United Kingdom
- **Anita De Rossi, PhD** - AIDS Reference Center, Italy
- **Marinella Della Negra, MD** - Hospital Emilio Ribas, Brazil
- **Brian Eley, MD** - Red Cross Children's Hospital, South Africa
- **Albert Faye, PhD** - Denis Diderot University, Paris, France
- **Rashida Ferrand, MBBS, MRCP, MSc, DRM&H** - London School of Hygiene & Tropical Medicine, United Kingdom
- **Tessa Goetghebuer, MD** - Hôpital St. Pierre, Belgium
- **Ellen Gould Chadwick, MD** - Northwestern University, United States
- **Valérie Leroy, MD** - Inserm, France
- **Chewe Luo, MD, PhD** - UNICEF, United States
- **Dorothy Mbori-Ngacha, MD** - University of Nairobi, Kenya
- **Sharon Nachman, MD** - SUNY Health Science Center at Stony Brook, United States
- **Julie Nelson, MD** - Retrovirology Core Laboratory, United States
- **Paul Palumbo, MD** - Dartmouth-Hitchcock Medical Center, United States
- **Martina Penazzato, MD, DTMH, MSc, PhD** - WHO, United Kingdom
- **Jorge Pinto, MD, DSc** - Universidade Federal de Minas Gerais, Brazil
- **Thanyawee Puthanakit, MD** - Chulalongkorn University, Thailand
- **Natella Rakhmanina, MD, PhD, FAAP, AAHIVS** - Children's National Medical Center, United States
- **Theodore Ruel, MD** - University of California, San Francisco, United States
- **George Siberry, MD, MPH** - National Institutes of Health, United States
- **Lynda Stranix-Chibanda, MBChB, MMED** - University of Zimbabwe, Zimbabwe
- **Graham Taylor, MD** - Imperial College London, United Kingdom
- **Claire Thorne, BA, MSc, PhD** - UCL, Institute of Child Health, United Kingdom
- **Marissa Vicari, MA** - International AIDS Society, Switzerland
- **Rachel Vreeman, MD, MS** - Indiana University, United States



PROGRAM DESCRIPTION

This 2-day global workshop will be organized in both **face-to-face and virtual** format. By bringing together experts from different disciplines with presentations in a variety of formats, the workshop offers a collaborative setting where the latest developments are presented, discussed, interrogated, and evaluated. The workshop has developed a reputation for being a premiere venue to present new scientific findings in the field of pediatric HIV. Meeting attendance has escalated from 125 in 2013 to over 300 participants at the 10th workshop in 2018. Meeting evaluations routinely completed by participants are highly favorable and confirm the importance of this meeting for researchers and clinicians working in pediatric HIV.

Furthermore, as this is the only workshop that allows concentrated focus on these scientific domains, it provides a unique venue to disseminate results, analyze study findings, and consider implications for service delivery, clinical care, and future research.

Hybrid Workshop

In light of the COVID-19 pandemic and associated travel restrictions, the format of the 2020 edition of the workshop will be adapted to enable the participation of international speakers and audiences who are unable to travel to the meeting location. The program will offer a hybrid-learning approach by combining live and virtual components. Lectures given by international speakers, who cannot attend the meeting in person, will be pre-recorded and broadcasted during the live event. This will be followed by a livestreamed Q&A session during which speakers will be available online in real time. They will also take part in livestreamed roundtables in real time to further enhance interactivity. In a similar way, the audience can choose to join the meeting in person or virtually. All plenary sessions will be livestreamed. Interactive platforms for real time Q&A sessions, chat rooms, and roundtables will provide an immersive experience to the virtual audience.

In this way, we aim to deliver the much-needed program in an optimal and convenient manner to all participants, reducing risk to their personal as well as public health, and circumventing challenges imposed by the current global pandemic. The hybrid workshop is anticipated to attract a broader audience, far beyond the conference walls, and thus increase the reach and educational impact of the program.

Abstracts

The meeting is abstract-driven, with an average of 15-20 oral abstracts and 80-100 poster presentations. The workshop also has an extraordinary record of supporting scientific achievement as demonstrated in the success across the cascade from abstract presentation to publication. A survey was conducted among investigators with oral abstract presentations at the past four workshops, 2013-2016. Of 78 oral abstracts presented, 45 (58%) have resulted in publication with a mean impact factor of 5.51. Papers have been published in *Lancet HIV*, *AIDS*, *PLOS Medicine*, *JAIDS*, and a host of other journals demonstrating the high level of interest in these scientific domains.

Accreditation

We aim to submit an application to the EACCME® for CME accreditation of this event.

Topic Highlights

- HIV therapeutics
- New therapies and formulations, including long-acting formulations and immune-based therapies
- Drug-drug interactions, such as antiretroviral and tuberculosis drugs, and antiretroviral drugs and hormonal contraceptives
- Short-term and long-term effects of treatment in HIV-infected individuals and in utero exposure to antiretroviral drugs in HIV-exposed but uninfected children
- Coinfections and their treatment, such as tuberculosis, hepatitis B and C infections, and HPV infection
- Cure and remission research
- Comorbidities including metabolic and organ-system specific (e.g., neurologic/neuropsychiatric)
- HIV prevention, including new modalities for prevention of mother-to-child HIV transmission and prevention of new infections in adolescents and women



OUTCOME EVALUATION

To assess and evaluate the outcomes of this workshop, **Virology Education** provides each delegate with a detailed feedback form in which they can anonymously assess the speakers, the relevance of each lecture, whether or not the meeting objectives were met, their intent to change, the rationale behind their motivation to attend, the general organization of the workshop, and much more. We encourage participants to share their ideas and suggestions for future workshops, as well as their educational needs, in order to further improve the program and ensure that it matches the needs of participants.

All the questions are then fully analyzed and a comprehensive report is created and shared with the committee members. These reports help us to better understand the needs of our delegates and how to further improve the workshop in the future. For a maximum response rate, we invite the chairs of each session to encourage the participants to take a few minutes and complete the feedback forms. We are also introducing a web-based application to allow participants access to the feedback forms electronically.

In addition to the on-site evaluation of the workshop, we also evaluate the registration and abstract submission processes, as well as the scholarship process. We ask delegates to fill in short questionnaires that help us to improve all processes, including registration, abstract submission, or grant application. We are committed to continuously improving the overall workshop experience and the scientific and clinical impact of our workshops.

We also assess knowledge and incorporate quizzes into the workshop sessions. This serves to further engage participants in the workshop and the content, while also giving us insight into participants' level of background knowledge. We are moving towards incorporating more pre- and post-test quizzes in order to assess knowledge increase in the coming years.

Expected Outcomes

In the last edition of this workshop, **96%** of participants reported they intend to incorporate the new information into their clinical practice.

We aim to measure and enhance the impact of this conference through:

- Measuring intent to change and analyzing ways to increase it
- Sharing meeting videos and presentations with a wide global audience and measuring reach (number of views, downloads, etc.)
- Measuring knowledge increase through pre- and post-tests

🗨️ We are committed to continuously improving the overall workshop experience and the scientific and clinical impact of our workshops. 🗨️



This meeting has been previously supported by:



Previous endorsers include:





SPONSOR OPPORTUNITIES

Hybrid conferences such as the [International Workshop on HIV Pediatrics](#) allow participants to experience our educational programs either in person or virtually and produces more opportunities for our supporters to interact with our audience. By supporting the [International Workshop on HIV Pediatrics](#), you can connect with clinicians and researchers from academia, research institutes, and GOs/NGOs, both face-to-face and online. By merging in-person communication and virtual elements, the hybrid conference format is an optimal solution in light of the current circumstances.

Why supporting is beneficial to your organization:

- REACH NEW AUDIENCES – Gives you opportunities to network and share your company message with a broader audience via virtual or in-person participation;
- PARTICIPATE CONVENIENTLY – Join and contribute to this educational initiative from home or in person; and
- MEET YOUR GOALS – Interact with participants and organizations in your target audience from across the globe.

We are pleased to provide the following opportunities and benefits to further your business. Get in touch with us to discuss a custom package or find out more about these support opportunities.

Exposure*

We provide several opportunities for acknowledging your support:

- Recognition via banner on high-traffic registration and meeting webpages;
- Pre-event recognition via attendee email communications;
- Acknowledgment prior to and during livestreamed sessions;
- On-site recognition via banners, flyers, and in the program book;
- Your logo on our monthly newsletters, delivered to thousands of opt-in subscribers;
- Recognition on our social media channels;
- Opportunities to produce video content embedded onto the meeting website to be viewed by our participants;
- Logo recognition on (e-)conference bag;
- Opportunity to organize a private dinner with meeting faculty

Contribute to the program*

- Opportunities to organize a symposium or event before, during, or after the meeting;
- Complimentary attendance as a (virtual) participant and join in on discussions.

Exhibition*

- Opportunity to organize a virtual or physical exhibit;
- Interact, chat, and share information through 1on1 conversations with participants using our virtual exhibition platform.

Scholarships

To make it possible for healthcare professionals from different regions, levels and backgrounds to be able to attend our workshop, we have developed a grant-based system through which we can independently support delegates. Through supporting our scholarship system, you and other pharmaceutical industry partners help us to ensure the selection of healthcare professionals that will most benefit from attending our workshop, and thereby guarantee a relevant audience and a higher impact of our workshop.

The grants are supported by the financial contributions allocated by our sponsors. A review committee of selected experts reviews scholarship applications in an independent and rigorous process. Priority is given to applicants who have actively participated in original research or scientific work that is being presented at the meeting and/or those who will profit most from participating in order to improve their daily clinical management and research.

* Dependent on the sponsorship level

Other benefits are described under various sponsorship levels

VIROLOGY EDUCATION



With over 20 years of experience, **Virology Education** is a leading provider of innovative scientific and educational programs worldwide. Our programs provide excellent platforms for scientific exchange, education, and knowledge-sharing tailored to the needs of healthcare professionals in the fields of infectious diseases, pharmacology, liver disease, and more. Our activities include the initiation and organization of real-time and online platforms for international exchange, knowledge-sharing, and education for medical professionals. We have developed long-standing collaborations with world-reknowned experts and work together with other important stakeholders to achieve the greatest impact for our programs and to provide top quality scientific content. Our programs range from international abstract-driven workshops to small- and large-scale educational series, masterclasses, advisory boards, expert roundtables, satellite symposia, and more.

Biltstraat 106
3572 BJ Utrecht
The Netherlands
www.virology-education.com
info@virology-education.com
+31 30 230 7140



Karin Siebelt, MSc
Project Manager
karin@vironet.com



Wilco Keulen, PhD
Senior Scientific Manager
wilco@vironet.com

More than 50 programs are planned for **2020** in more than **20 different cities** around the globe! In addition, **13+ online activities** planned for 2020.



OUR IMPACT IN 2019

46 programs | 6.330 participants | 2.230 accepted abstracts
35% of participants were Clinician/Physicians | 25% were researchers
86% of the respondents agreed that attending our program was beneficial for their patients